Surprisingly, our data also show discordance between the overall response rate and PFS as there was no improvement in the depth of response in our meta-analysis, even with an anti-CD38 containing regimen, while we detected a highly significant PFS advantage with the use of daratumumab.
← all excerpts
Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.
1
—
—